Glycemic Control with Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

Launched by NABIQASIM INDUSTRIES (PVT) LTD · Mar 1, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to manage type 2 diabetes using a combination of three medications—empagliflozin, linagliptin, and metformin—packed into one convenient pill. The goal is to see how well this triple combination works for controlling blood sugar levels and improving the overall quality of life for patients with diabetes. Researchers will also evaluate how easy it is for patients to stick to this treatment, its effect on weight, and the risk of low blood sugar episodes.

To participate in the trial, individuals must be between 18 and 80 years old, have been diagnosed with type 2 diabetes for at least six months, and have a specific blood sugar level that meets the study's criteria. They should also be currently taking at least two diabetes medications. If you or a loved one meets these criteria, you may be eligible to join this important study, which aims to find a more effective way to manage diabetes and improve patient satisfaction with their treatment.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • 1. Patients of any gender
• • 2. Patients aged between 18-80 years
• • 3. Patients having HbA1c 8 % or above
• • 4. Patients diagnosed with type II diabetes (more than at least 06 months)
• • 5. Patients already on at least 02 or more anti-diabetic agents
• • 6. Patients not allergic to empagliflozin, linagliptin, or metformin
• • Exclusion criteria
• • 1. Patients with age less than 18
• • 2. Patients with Type-I diabetes
• • 3. Patients having diabetes for less than 06 months
• • 4. Patients on GLP-1 and GIP
• • 5. Patients who are pregnant or lactating females
• • 6. Patients with decompensated chronic liver disease (DCLD)
• • 7. Patients with eGFR less than 30 ml
• • 8. Patients with end-stage heart failure (NYHA Class 4)
• • 9. Patients who are allergic to empagliflozin, linagliptin, or metformin
• • 10. Patients who are not willing to consent
• • 11. Patients who are unable to give medical history